MARATTO

review · Zagazig University Medical Journal

Possible Relation between CD9 and acute leukemia: A Review Article

Abstract

Background: Due to a cascade of mutations that occur throughout the intricate hematopoiesis process, acute leukemia develops. Myeloid cells and lymphoid cells (B- and T lymphocytes) are the two main cell lineages that all pluripotent cells in the bone marrow multiply into. Nowadays, CD9 can be found expressed in many different kinds of cells and tissues, several cell types, including malignant cells, stromal cells, epithelial cells, endothelial cells, and hematopoietic cells. We intended to outline possible roles in the Possible Relationship between CD9 and acute leukemia. An intriguing strategy to eradicate LSCs and avoid relapses in the AML could involve focusing on CD9, this could be accomplished through the utilization of the chimeric antigen receptor (CAR) T-cell therapy or monoclonal antibodies. Because CD9 is expressed on monocytes and these cells are involved in the AML by generating interleukin 1, reducing their numbers could be an intriguing prospect in this disease

Research topics

  • Cell Adhesion Molecules Research
  • Chemokine receptors and signaling
  • Immune Response and Inflammation

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/zumj.2024.268176.3160

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.